Future directions of drug-eluting stents

Journal of Interventional Cardiology

Volumn 22, Issue SUPPL. 1, 2009, Pages

  Kukreja, Neville ^a   Onuma, Yoshinobu ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLIMUS; EVEROLIMUS; NOVOLIMUS; RAPAMYCIN; RAPAMYCIN DERIVATIVE; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ANATOMICAL VARIATION; BIODEGRADABLE IMPLANT; CLINICAL PRACTICE; CLINICAL RESEARCH; CORONARY STENT; DRUG DESIGN; DRUG ELUTING STENT; HEART INFARCTION; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; MATERIAL COATING; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; RISK MANAGEMENT;

EID: 65649150675     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2009.00455.x     Document Type: Review

References (67)

1. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987 316 : 701 706. (Pubitemid 17036474)
2. Serruys PW, Kutryk MJB, Ong ATL. Coronary-artery stents. N Engl J Med 2006 354 : 483 495. (Pubitemid 43200299)
3. Kastrati A, Schomig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997 30 : 1428 1436. (Pubitemid 27486458)
4. Rajagopal V, Rockson SG. Coronary restenosis: A review of mechanisms and management. Am J Med 2003 115 : 547 553. (Pubitemid 37352801)
5. Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: Five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004 110 : 1226 1230. (Pubitemid 39202337)
6. Babapulle MN, Joseph L, Belisle P, et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004 364 : 583 591. (Pubitemid 39094175)
7. Roiron C, Sanchez P, Bouzamondo A, et al. Drug eluting stents: An updated meta-analysis of randomised controlled trials. Heart 2006 92 : 641 649.
8. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007 356 : 989 997. (Pubitemid 46376799)
9. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007 356 : 998 1008. (Pubitemid 46376800)
10. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 2007 370 : 937 948. (Pubitemid 47393576)
11. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007 115 : 2344 2351. (Pubitemid 46685903)
12. Morice M-C, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002 346 : 1773 1780. (Pubitemid 34586912)
13. Aoki J, Serruys PW, van Beusekom H, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: The HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005 45 : 1574 1579. (Pubitemid 40704488)
14. Duckers HJ, Silber S, Winter Rd, et al. Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: Evaluation of an endothelial progenitor cell capturing stent. EuroInterv 2007 3 : 67 75.
15. Duckers HJ, Soullié T, Heijer Pd, et al. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: Final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent)™. EuroInterv 2007 3 : 350 358.
16. Co M, Tay E, Lee CH, et al. Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: Intermediate- to long-term clinical follow-up. Am Heart J 2008 155 : 128 132. (Pubitemid 350234778)
17. Windecker S, Simon R, Lins M, et al. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: The TiNOX Trial. Circulation 2005 111 : 2617 2622. (Pubitemid 40740861)
18. Karjalainen P, Ylitalo A, Niemela M, et al. Titanium-nitride-oxide coated stents versus paclitaxel-eluting stents in acute myocardial infarction: A 12-months follow-up report from the TITAX AMI trial. EuroInterv 2008 4 : 234 241.
19. Abizaid AC, De Ribamar Costa J, Whitbourn RJ, et al. The CardioMind coronary stent delivery system: Stent delivery on a.014" guidewire platform. EuroInterv 2007 3 : 154 157.
20. Grube E, Sievert H, Hauptmann K, et al. Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results. EuroInterv 2008 4 : 71 76.
21. Stella PR, Mueller R, Pavlakis G, et al. One year results of a new in situ length-adjustable platform with a biodegradable Biolimus A9 eluting polymer: Results of the CUSTOM-II trial. EuroInterv 2008 4 : 200 207.
22. Ormiston JA, Webster MWI, Jack SE, et al. Drug-eluting stents for coronary bifurcations: Bench testing of provisional side-branch strategies. Catheter Cardiovasc Interv 2006 67 : 49 55. (Pubitemid 43062609)
23. Hoye A, Iakovou I, Ge L, et al. Long-term outcomes after stenting of bifurcation lesions with the "crush" technique: Predictors of an adverse outcome. J Am Coll Cardiol 2006 47 : 1949 1958.
24. Ge L, Airoldi F, Iakovou I, et al. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: Importance of final kissing balloon post-dilation. J Am Coll Cardiol 2005 46 : 613 620. (Pubitemid 41132686)
25. Ge L, Iakovou I, Cosgrave J, et al. Treatment of bifurcation lesions with two stents: One year angiographic and clinical follow up of crush versus T stenting. Heart 2006 92 : 371 376. (Pubitemid 43295110)
26. Steigen TK, Maeng M, Wiseth R, et al. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: The Nordic bifurcation study. Circulation 2006 114 : 1955 1961. (Pubitemid 44665390)
27. Tsuchida K, Colombo A, Lefevre T, et al. The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: Insights from the Arterial Revascularization Therapies Study part II (ARTS II). Eur Heart J 2007 28 : 433 442. (Pubitemid 47343573)
28. Abizaid A, de Ribemar Costa J, Alfaro V, et al. Bifurcated stents: Giving to Caesar what is Caesar's. EuroInterv 2007 2 : 518 525.
29. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006 113 : 1108 1113. (Pubitemid 43754278)
30. Lefevre T, Ormiston J, Guagliumi G, et al. The FRONTIER stent registry: Safety and feasibility of a novel dedicated stent for the treatment of bifurcation coronary artery lesions. J Am Coll Cardiol 2005 46 : 592 598. (Pubitemid 41132683)
31. Duchamp J, Boeke-Purkis K. Abbott Vascular's everolimus eluting side branch access stent. EuroInterv 2007 2 : 509 511.
32. Ormiston J, Webster M, El-Jack S, et al. The AST petal dedicated bifurcation stent: First-in-human experience. Catheter Cardiovasc Interv 2007 70 : 335 340. (Pubitemid 350194978)
33. Laborde J-C, Borenstein N, Behr L, et al. Stentys coronary bifurcation stent. EuroInterv 2007 3 : 162 165.
34. Grube E, Buellesfeld L, Neumann FJ, et al. Six-month clinical and angiographic results of a dedicated drug-eluting stent for the treatment of coronary bifurcation narrowings. Am J Card 2007 99 : 1691 1697. (Pubitemid 46881145)
35. Onuma Y, Müller R, Ramcharitar S, et al. Tryton I, First-In-Man (FIM) study: Six month clinical and angiographic outcome, analysis with new quantitative coronary angiography dedicated for bifurcation lesions. EuroInterv 2008 3 : 546 552.
36. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet 2008 372 : 1163 1173.
37. ® stent: 6-month angiographic and 30 month clinical follow-up results from the Series I prospective study. EuroInterv 2008 4 : 59 63.
38. Ge J, Qian J, Wang X, et al. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries. Catheter Cardiovasc Interv 2007 69 : 198 202. (Pubitemid 46214251)
39. Lee CH, Lim J, Low A, et al. Sirolimus-eluting, bioabsorbable polymer-coated constant stent (Cura) in acute ST-elevation myocardial infarction: A clinical and angiographic study (CURAMI Registry). J Invasive Cardiol 2007 19 : 182 185. (Pubitemid 46558000)
40. Dawkins K, Verheye S, Schühlen H, et al. The European cobalt STent with Antiproliferative for Restenosis trial (EuroSTAR): 12 month results. EuroInterv 2007 3 : 82 88.
41. Krucoff MW, Kereiakes DJ, Petersen JL, et al. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: Primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol 2008 51 : 1543 1552.
42. Vranckx P, Serruys PW, Gambhir S, et al. Biodegradable-polymer-based, paclitaxel-eluting Infinnium™ stent: 9-Month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study. EuroInterv 2006 2 : 310 317.
43. Meredith I, Worthley S, Whitbourn R, et al. The next-generation Endeavor™ Resolute™ stent: 4-month clinical and angiographic results from the Resolute™ first-in-man trial. EuroInterv 2007 3 : 50 53.
44. Wessely R, Hausleiter J, Michaelis C, et al. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 2005 25 : 748 753. (Pubitemid 40463864)
45. Mehilli J, Kastrati A, Wessely R, et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006 113 : 273 279. (Pubitemid 43754385)
46. Ruef J, Storger H, Schwarz F, Haase J. Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions. Catheter Cardiovasc Interv 2008 71 : 333 339.
47. Mehilli J, Byrne RA, Wieczorek A, et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 2008 29 : 1975 1982.
48. Rajtar A, Kaluza G, Yang Q, et al. Hydroxyapatite-coated cardiovascular stents. EuroInterv 2006 2 : 113 115.
49. Kollum M, Farb A, Schreiber R, et al. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Catheter Cardiovasc Interv 2005 64 : 85 90. (Pubitemid 40069896)
50. Palmaz JC, Sibbitt RR, Reuter SR, et al. Expandable intraluminal graft: A preliminary study. Work in progress. Radiology 1985 156 : 73 77.
51. Roubin GS, Robinson KA, King SB, et al. Early and late results of intracoronary arterial stenting after coronary angioplasty in dogs. Circulation 1987 76 : 891 897. (Pubitemid 17151348)
52. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000 102 : 399 404. (Pubitemid 30490677)
53. Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: The BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv 2007 69 : 128 131. (Pubitemid 46052603)
54. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): A prospective open-label trial. Lancet. 2008 371 : 899 907.
55. Tanimoto S, Serruys PW, Thuesen L, et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 2007 70 : 515 523. (Pubitemid 47597022)
56. Kukreja N, Otsuka M, van Mieghem C, et al. Biodegradable drug eluting stents: Invasive and non-invasive imaging. EuroInterv 2006 2 : 403.
57. Tanimoto S, Bruining N, van Domburg RT, et al. Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. J Am Coll Cardiol 2008 52 : 1616 1620.
58. Erbel R, Di Mario C, Bartunek J, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: A prospective, non-randomised multicentre trial. Lancet 2007 369 : 1869 1875. (Pubitemid 46829357)
59. Eggebrecht H, Rodermann J, Hunold P, et al. Novel magnetic resonance-compatible coronary stent: The absorbable magnesium-alloy stent. Circulation 2005 112 : e303 e304. (Pubitemid 41697607)
60. Bose D, Eggebrecht H, Erbel R. Absorbable metal stent in human coronary arteries: Imaging with intravascular ultrasound. Heart 2006 92 : 892 (Pubitemid 43974046)
61. Kukreja N, Garcia-Garcia HM, Serruys PW. Invasive imaging techniques for the assessment of vulnerable plaque. Minerva Cardioangiol 2006 54 : 603 617.
62. Takano M, Yamamoto M, Inami S, et al. Long-term follow-up evaluation after sirolimus-eluting stent implantation by optical coherence tomography: Do uncovered struts persist? J Am Coll Cardiol 2008 51 : 968 969.
63. Rodriguez-Granillo GA, Garcia-Garcia HM, Mc Fadden EP, et al. In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol 2005 46 : 2038 2042. (Pubitemid 41713588)
64. Schaar JA, Van Der Steen AF, Mastik F, et al. Intravascular palpography for vulnerable plaque assessment. J Am Coll Cardiol 2006 47 : C86 C91.
65. Caplan JD, Waxman S, Nesto RW, et al. Near-infrared spectroscopy for the detection of vulnerable coronary artery plaques. J Am Coll Cardiol 2006 47 : C92 C96.
66. Gonzalo N, Serruys PW, Barlis P, et al. Multi-modality intra-coronary plaque characterization: A pilot study. Int J Cardiol 2008.
67. Granada JF, Pomeranz M, Heringes J, et al. vProtect luminal shield system. EuroInterv 2007 3 : 416 419.